Sutro Biopharma, Inc.
STRO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001382101
No open-market purchases or sales by Sutro Biopharma, Inc. insiders were filed in the last 90 days; 100 institutions reported holding it in 13F filings for Q2 2026, worth $545.7M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Sutro Biopharma, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 120 | 1 | 109 | −10 |
| Shares | 54.1M | 98.4K | 55.9M | +1.89M (+3.5%) |
| Value | $251.6M | $457.3K | $194.3M | −$56.8M (−22.6%) |
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (7)
Institutions that held Sutro Biopharma, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Oconnor LLC | 330,000 | $1.15M | 0.02% |
| Gsa Capital Partners LLP | 67,754 | $235.0K | 0.02% |
| SG Americas Securities, LLC | 32,465 | $113.0K | 0.00% |
| HSBC Holdings PLC | 27,771 | $97.6K | 0.00% |
| XTX Topco Ltd | 20,446 | $70.9K | 0.01% |
| Qube Research & Technologies Ltd | 4,953 | $17.2K | 0.00% |
| Comerica Bank | 280 | $971 | 0.00% |
Sold out (17)
Institutions that held Sutro Biopharma, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Opaleye Management Inc. | 307,000 | $1.43M |
| Balyasny Asset Management LLC | 214,021 | $995.2K |
| Two Sigma Investments, LP | 135,816 | $631.5K |
| D. E. Shaw & Co., Inc. | 40,723 | $189.4K |
| Soleus Capital Management, L.P. | 25,887 | $120.4K |
| Caxton Associates LP | 21,351 | $99.3K |
| Cubist Systematic Strategies, LLC | 16,517 | $76.8K |
| Point72 Middle East FZE | 15,069 | $70.1K |
| Y-Intercept (Hong Kong) Ltd | 14,190 | $66.0K |
| Algert Global LLC | 12,250 | $57.0K |
| Ergoteles LLC | 11,690 | $54.4K |
| Fairfield, Bush & Co. | 2,000 | $9.30K |
| Quadrant Capital Group LLC | 1,976 | $9.19K |
| Signaturefd, LLC | 941 | $4.38K |
| Lindbrook Capital, LLC | 67 | $312 |
| Baker Avenue Asset Management, LP | 45 | $209 |
| Group One Trading, L.P. | 34 | $158 |
Not filed for Q3 2023 yet (1)
Institutions that held Sutro Biopharma, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Tekla Capital Management LLC | 98,354 | $457.3K |